What is Aulos Bioscience?
Aulos Bioscience is a life science company focused on revolutionizing cancer patient care through highly differentiated immuno-oncology therapeutics. Established by ATP, a prominent life science venture capital firm, and Biolojic Design, a company specializing in computational antibody design, Aulos is initially concentrating on developing unique IL2 targeting antibodies. The company believes these therapeutics have the potential to become best-in-class treatments for solid tumors, addressing a critical unmet need in oncology.
How much funding has Aulos Bioscience raised?
Aulos Bioscience has raised a total of $60M across 1 funding round:
Series A
$60M
Series A (2023): $60M with participation from ATP
Key Investors in Aulos Bioscience
ATP
ATP is a leading life science venture capital firm that invests in and builds companies at the forefront of scientific innovation. Their involvement suggests a strategic focus on early-stage biotechnology with high therapeutic potential.
What's next for Aulos Bioscience?
With this major enterprise-level funding, Aulos Bioscience is poised for significant expansion and advancement of its therapeutic pipeline. The strategic investment will likely accelerate the development and clinical validation of its IL2 targeting antibodies. This backing from ATP, a venture capital firm with a strong track record in life sciences, signals confidence in Aulos's innovative approach and its potential to disrupt the solid tumor treatment landscape. The company's focus on computationally designed antibodies suggests a data-driven and efficient development process, positioning it for future growth and potential market leadership.
See full Aulos Bioscience company page
